STAT News

STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk

When it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus. Such is the case with a therapy from Neurocrine Biosciences.

Por STAT News

1 minuto de lectura
Compartir
STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk
STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas